IPDAC
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
ImpediMed Limited - Option Expiring 31-Mar-2021 Deferred
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in IPDAC
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in IPDAC
N/A
IPDAC investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in IPDAC also invest in...
Want more shares? Try these...
ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 83 full-time employees. The company went IPO on 2007-10-24. The firm uses bioimpedance spectroscopy (BIS) technology to generate data to maximize patient health. The firm designs and manufactures medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition. The Company’s SOZO Digital Health Platform is a Food and Drug Administration (FDA)-cleared bioimpedance spectroscopy (BIS) solution for the clinical assessment of lymphedema. SOZO uses its BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its product SFB7 measures fluid status and tissue composition for clinical and research applications. Its ImpediVET is a single-channel, tetrapolar bioimpedance spectroscopy (BIS) device that measures fluid status and tissue composition for veterinary applications.
🙌 Performance (5Yr p.a)
-10.92%
📊 Share price
$0.05 AUD
🩺 HEALTH CARE